Bipolar disorder is a highly heritable psychiatric disorder that features episodes of mania and depression. We performed the largest genomewide association study to date, including 20,352 cases and 31,358 controls of European descent, with followup analysis of 881 sentinel variants at loci with P<1x10 4 in an independent sample of 9,412 cases and 137,760 controls. In the combined analysis, 30 loci achieved genomewide significance including 18 novel loci. These significant loci contain genes encoding ion channels and neurotransmitter transporters ( CACNA1C , GRIN2A , SCN2A, SLC4A1 ), synaptic components ( RIMS1, ANK3 ), immune and energy metabolism components, and multiple potential therapeutic targets for mood stabilizer drugs.
Genomewide association study identifies 30 Loci Associated with Bipolar Disorder.
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BD can be divided into two main clinical subtypes 5, 6 : bipolar I disorder (BD1) and bipolar II disorder (BD2). In BD1, manic episodes typically alternate with depressive episodes during the course of illness. Diagnosis of BD2 is based on the lifetime occurrence of at least one depressive and one hypomanic (but no manic) episode . Although modern diagnostic systems retain the Kraepelinian dichotomy 7 between BD and schizophrenia, the distinction between the two disorders is not always clearcut, and some patients displaying clinical features of both disorders may receive a diagnosis of schizoaffective disorder (SAB). Likewise, in genetic studies the two diagnoses are usually treated separately, although recent epidemiological and molecular genetic studies provide strong evidence for some overlap between the genetic contributions to their etiology 2, 8 .
Recent genomewide association studies (GWASs) in BD have identified a number of significant associations between disease status and common genetic variants [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] . The first large collaborative BD GWAS by the multinational Psychiatric Genomics Consortium (PGC) Bipolar
Disorder Working Group comprised 7,481 BD patients and 9,250 controls and identified one novel and three known genomewide significant loci 9 . Three subsequent metaanalyses that included the PGC BD data 10, 12, 18 identified an additional 5 loci.
Estimates of the proportion of variance in liability attributable to genomewide SNPs (SNP heritability) indicate that~¼⅓ of the heritability for BD is due to common genetic variants 8 . To date, only a small fraction of this heritability is explained by associated loci but results from other human complex traits suggests that many more will be identified by increasing the sample size of the GWAS Some of our findings reinforce specific hypotheses regarding BD neurobiology; however, the majority of the findings suggest new biological insights.
RESULTS

GWAS of bipolar disorder (BD)
We performed a GWAS metaanalysis of 32 cohorts from 14 countries in Europe, North Figure 1 ) . The LDscore regression intercept was not significantly different from 1, indicating that the observed genomic inflation is indicative of polygenicity rather than stratification or cryptic population structure 25 . This was further supported by LDscore regression which yields a highly significant We find a marked increase in polygenic risk score (PRS) variance explained compared to previous studies (weighted mean observed Nagelkerke's R 
Followup of suggestive loci in additional samples
We metaanalysed all lead SNPs within LD clumps (a total of 881 SNPs) which were significant at P<1x10 ) and 69% or 585 SNPs had the same direction of effect (sign test P < 2x10 16 ), indicating that within this set additional associations remain to be discovered in future GWAS.
Lead SNPs for loci achieving genomewide significance are tabulated in 
BD subtype GWAS
We performed secondary analyses of the GWAS dataset, focusing on three clinically 
Shared loci and genetic correlations with SCZ, Depression and other GWAS traits
In a series of conditional analyses within bipolar risk loci and genomewide genetic correlation analyses, we examined the relationships of BD to other psychiatric disorders and other traits for which GWAS have been conducted. Looking at individual loci, 8 of the 30 genomewide significant BD loci also harbor SCZ associations [27] [28] [29] . Conditional analyses suggest that the BD and SCZ associations are not independent at 5 of the 8 shared loci ( Supplementary   Table 6 ), the exceptions being the NCAN , TRANK1 and chr7q22.3 (105Mb) loci. We did not find any BD loci (at p<5x10 Table 7A ). We found significant genetic correlations between BD and other psychiatricrelevant traits ( Supplementary Table 7B Table 6 ). However, among these, only educational attainment showed significant genomewide genetic correlations with bipolar disorder ( Supplementary   Table 7B ).
Systems biology and functional analyses of GWAS results
In order to try to identify genes with functional variation that might explain the associations, we used Mendelian randomisation (SMR) 39 to integrate our bipolar disorder GWAS with eQTL data from dorsolateral prefrontal cortex 40 as well as a largesample whole blood eQTL dataset 41 . This identified six transcriptomewide significant genes without signs of heterogeneity between GWAS and eQTL signals ( Supplementary Table 9 ). Among these, expression of LMAN2L is We tested for functional genomic enrichment in our bipolar disorder GWAS using Table 11 ).
Finally, we used MAGMA 
DISCUSSION
We carried out the largest BD GWAS to date, aiming to identify genetic variants associated with BD, examine the genetic relationships among BD, BP1, BP2, SAB and SCZ, and identify biological pathways related to BD through systems genomics. Our GWAS analysis identified 19 genomewide significant loci, including 12 loci not previously associated with BD.
Previous BD GWAS have reported a total of 20 loci significantly associated with BD [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] ; twelve of these previously reported loci were not genomewide significant in our GWAS analysis but had previously known loci as genomewide significant, and a total of twenty novel bipolar disorder risk loci.
Of these 30 overall loci, 8 also harbor SCZ associations [27] [28] [29] . Conditional analyses suggest that the BD and SCZ associations are not independent at 5 of the 8 shared loci ( Supplementary   Table 6 ), the exceptions being the NCAN , TRANK1 and chr7q22.3 (105Mb) loci. TRANK1 is our strongest associated locus; differential BD and SCZ associations there and our other loci may represent opportunities to understand the genetic distinctions between these closely related disorders. We did not find BD loci that overlap with those associated with major depression 30 .
The lack of overlapping loci with major depression may be due to the variants underlying the genetic correlation seen between major depression and BD having individual lower effect sizes than our BD GWAS loci.
The confirmed association with CACNA1C and other voltagegated calcium channels . Other biological pathways implicated by loci associated with BD include energy metabolism and calcium channel processes. These process are both important in neuronal hyperexcitability 47 , an excess of which has been reported in iPSC derived neurons from BD patients, where lithium, a classic mood stabilizing drug, differentially affects neuronal excitability 48 .
Other genes mapping to associated loci include those coding for neurotransmitter channels ( GRIN2A ), ion channels and transporters ( SCN2A, SLC4A1 ) and synaptic components ( RIMS1, ANK3 ).
The estimated variance explained by polygenic risk scores (PRS) based on our BD GWAS data is ~8% (observed scale; 4% on the liability scale 49 ), an increase from 2.8% from our previous study 9 . Using PRS for other psychiatric phenotypes, we identified differential sharing of risk alleles between common subtypes of BD (BD1 and BD2) with schizophrenia and major depression, effects that are mirrored by the patterns of LD score genetic correlations between the traits (Figure 2 ). In particular we were able to show that BD1 is genetically more closely related to schizophrenia while BD2 is more closely related to major depression. This finding may make a useful contribution to a topic which has been much debated 3 although further studies are needed to examine the genetic relationship between severe recurrent depression, for which we did not have GWAS data, and BD2
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. Likewise, while we see significant genetic correlations of BD with educational attainment, we do not see significant r g s of BD with either adult or childhood IQ, suggesting the role of BD genetics in increased educational attainment, as suggested by epidemiological studies 51 , may be independent of general intelligence, despite its significant r g with educational attainment (r g = 0.70, P = 2.5×10
−287
). Our findings address key clinical questions and suggest potential new biological mechanisms for bipolar disorder.
Online Methods
Methods.
GWAS cohorts. We performed GWAS metaanalysis of 32 cohorts from 14 countries in Europe, North America and Australia ( Supplementary Table 1A . Cases were required to meet international consensus criteria (DSMIV, ICD9, or ICD10) for a lifetime diagnosis of BD established using structured diagnostic instruments from assessments by trained interviewers, clinicianadministered checklists, or medical record review (see Supplementary Note ). Controls in most cohorts were screened for the absence of lifetime psychiatric disorders and randomly selected from the population. We also conducted BD subtype GWAS (see Supplementary Note for details) .
Followup cohorts. We metaanalysed the 881 variants that had a p<10 4 in the BD GWAS data with data from Europeanancestry cohorts (totaling 9,412 cases and 137,760 controls).
Supplementary Table 1 summarizes the source and inclusion/exclusion criteria for cases and controls for each cohort. Genotyping and quality control. Genotyping procedures can be found in the GWAS reports or reference publications for each cohort ( Supplementary Table 1 and Supplementary Note ). Individual genotype data for all GWAS cohorts and the iPSYCH cohort were processed using the PGC "ricopili" pipeline (URLs) for standardized quality control, imputation, and analysis
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. The followup cohorts from were processed by the collaborating research teams using comparable procedures. Quality control filters applied to each cohort included imputation marker INFO score ≥ 0.6 and allele frequencies ≥0.01 and ≤0.99. Quality control and imputation on the GWAS cohorts was performed according to standards from the PGC. SNPs and insertiondeletion polymorphisms were imputed using the 1000
Genomes Project multiancestry reference panel (URLs) 53 . Principal components based on ld independent SNPs were calculated to be used as covariates in final association analysis.
Further details of SNP and individual level QC can be found in the Supplementary Note.
Statistical analysis. In each cohort, logistic regression association tests were conducted for imputed marker dosages with principal components covariates to control for population stratification. Ancestry was evaluated using principal components analysis applied to directly
genotyped SNPs 54 . We tested 20 principal components for association with BD and included 6 principal components covariates for the GWAS cohorts; all other cohorts adopted similar strategies. The results were combined across samples using an inverseweighted fixed effects model 52 . For all GWAS cohorts, Xchromosome association results were conducted separately by sex, and then metaanalysed across sexes. X chromosome genotype data was not available for the followup cohorts.
Defining loci. GWA findings implicate genomic regions containing multiple significant SNPs ("loci"). These are not independent associations but result from LD between SNPs. We collapsed the significant SNPs to 30 loci via steps described in the Supplementary Note.
Polygenic risk score (PRS) analyses. To demonstrate the validity of our GWAS results, we conducted a series of PRS prediction analyses. Detailed results for all P value thresholds are reported for the anchor cohorts in Supplementary Table 14 . We next examined whether the PRSs for major depression and for SCZ differ between BD type I and type II cases using the entire GWAS cohort as the target sample. We tested the standardized PRS between BD I cases (N=8044) and BD II cases (N=3365) by regressing the scores on the two subtypes while adjusting for ancestry principal components and a batch (in this case, cohort) indicator ( Supplementary LD score regression was also used to partition by genomic features 42 . We also used LD score regression to estimate genetic correlation between BD and a range of other disorders, diseases, and human traits 56 . These calculations were done using the internal PGC GWA library and with
Relation of BD GWA findings to tissue and cellular gene expression. We used partitioned LD score regression to evaluate which somatic tissues and brain tissues were enriched for BD heritability. 57 We used summarydatabased Mendelian randomization (SMR) 39 to identify loci with strong evidence of causality via gene expression ( Supplementary Table 9 ). Since the aim of SMR is to prioritize variants and genes for subsequent studies, a test for heterogeneity excludes regions that may harbor multiple causal loci (pHET < 0.05).
DNA looping using HiC. To examine the 31 significant loci we conducted analysis of DNA looping between top SNPs and nearby genes. This did not yield any significant results; full methods can be found in the Supplementary Note .
Genewise and pathway analysis. Our approach was guided by rigorous method comparisons conducted by PGC members 44, 58 . P values quantifying the degree of association of genes and gene sets with BD were generated using MAGMA (v1.06) 44 . MAGMA was used to calculate genewide association by using Brown's method to combine SNP pvalues, accounting for the LD structure present in the gene. The resulting pvalues are then combined into aggregate pvalues (using Brown's method to correct for correlation between them), thereby increasing power across a range of genetic architectures. We used ENSEMBL gene coordinates for 19,079 genes giving a Bonferroni corrected P value threshold of 2.6x10 6 . These aggregate genewide pvalues are then used to perform rests of association enrichment in gene sets using a competitive analysis that tests whether genes in a gene set are more strongly associated with the phenotype than other gene sets, correcting for gene size, SNP density, and LD within and between genes.
We used Europeanancestry subjects from 1,000 Genomes Project (Phase 3 v5a, MAF ≥ 0.01) 53 for the LD reference. The gene window used was 35 kb upstream and 10 kb downstream to include regulatory elements.
Gene sets were compiled from multiple sources. The pathway map ( Supplementary Figure 5 ) was constructed using the kernel generative topographic mapping algorithm (kGTM) as described by 59 . See Supplementary Note for further details.
Genome build. All genomic coordinates are given in NCBI Build 37/UCSC hg19.
Availability of results. The PGC's policy is to make genomewide summary results public.
Summary statistics for our metaanalysis of the GWAS cohort samples are available on the PGC web site (URLs). Availability of genotype data for the anchor cohorts can be applied for via http://www.med.unc.edu/pgc/sharedmethods. For the expanded cohorts, interested users should contact the lead PIs of these cohorts (which are separate from the PGC). 
